Table 2.
Demographic, clinical and biochemical characteristics of COVID-19 patients at the time of hospital admission
| N | Age (years) |
Sex | BMI | VTE site | Padua score | Associated diseases | Ventilation | Time span between COVID-19 onset and VTE (days) | Time span between hospital admission and VTE (days) | Anticoagulant prophylactic therapy prescribed at the time of VTE diagnosis (dose) | Ward of admission | PaO2/FiO2 | PLT (× 109/L) | PLR | CRP (mg/dl) | LDH (U/L) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 70 | M | 33 |
Upper DVT (Unilateral axillar vein) |
5 | Asthma, OSAS, DM2 |
Non mechanical (CPAP) |
16 | 9 |
Enoxaparin (4000 UI/day) |
Internal Medicine | 109 | 104 | 20.8 | 6.1 | 965 | Dead |
| 2 | 50 | M | 28 |
Lower DVT (Bilateral femoral vein) |
5 | Hypertension |
Non mechanical (Venturi mask) |
15 | 0 | None | Internal Medicine | 282 | 241 | 301.2 | 25.2 | 250 | Alive |
| 3 | 62 | M | 31 |
Upper DVT (Bilateral subclavian vein) |
6 | Hypertension, DM2, ischemic cardiopathy |
Non mechanical (CPAP) |
11 | 4 |
Enoxaparin (4000 UI/day) |
Pneumology | 266 | 139 | 278.0 | 21.5 | 599 | Alive |
| 4 | 55 | M | 26 |
Upper DVT (Unilateral jugular vein) |
6 | None | Mechanical | 16 | 6 |
Calcic heparin (7500 UI × 3/day) |
ICU | 292 | 263 | 461.4 | 6.2 | 676 | Alive |
| 5 | 68 | M | 32 |
Upper DVT (Unilateral axillar vein) |
5 | Hypertension, ischemic cardiopathy |
Non mechanical (Venturi mask) |
10 | 4 |
Enoxaparin (4000 UI/day) |
Pneumology | 250 | 149 | 402.7 | 28.7 | 576 | Alive |
| 6 | 62 | M | 31 |
PE (Bilateral segmental PE) |
6 | DM2 |
Non mechanical (CPAP) |
10 | 3 |
Enoxaparin (4000 UI/day) |
Infectious Diseases | 182 | 106 | 66.2 | 11.5 | 334 | Alive |
| 7 | 59 | M | 30 |
Upper DVT (Unilateral subclavian vein) |
6 | Hypertension | Mechanical | 15 | 5 |
Calcic heparin (7500 UI × 3/day) |
Internal Medicine | 78 | 246 | 492.0 | 32.4 | 463 | Alive |
| 8 | 65 | M | 31 |
Lower DVT (Unilateral femoral-popliteal axis) |
5 | None |
Non mechanical (Venturi mask) |
11 | 4 | Enoxaparin (4000 UI/day) | Infectious Diseases | 55 | 299 | 498.3 | 22.4 | 423 | Alive |
| 9 | 56 | M | 28 |
Lower DVT (Unilateral femoral vein) |
6 | Hypertension |
Non mechanical (CPAP) |
16 | 8 |
Fondaparinux (2.5 mg/day) |
Infectious Diseases | 294 | 184 | 153.3 | 3.5 | 381 | Alive |
| 10 | 64 | F | 35 |
PE (Unilateral subsegmental PE) |
6 | Hypertension, obesity |
Non mechanical (CPAP) |
14 | 7 |
Enoxaparin (4000 UI/day) |
Infectious Diseases | 112 | 144 | 204.4 | 10.0 | 791 | Alive |
| 11 | 70 | M | 30 |
Lower DVT (Unilateral femoral vein) |
6 | Chronic kidney disease, hypertension | Mechanical | 13 | 3 |
Calcic heparin (5000 UI × 3/day) |
Infectious Diseases | 84 | 105 | 210.0 | 37.8 | 807 | Alive |
| 12 | 70 | M | 34 |
Upper DVT (Bilateral axillar vein) |
7 | Hypertension, obesity, DM2 |
Non mechanical (Venturi mask) |
11 | 5 |
Enoxaparin (4000 UI/day) |
Pneumology | 52 | 183 | 183.0 | 12.1 | 604 | Alive |
| 13 | 62 | F | 28 |
Lower DVT (Unilateral femoral–popliteal axis) |
6 | None |
Non mechanical (Venturi mask) |
14 | 5 |
Enoxaparin (4000 UI/day) |
Infectious Diseases | 76 | 292 | 7933.6 | 31.5 | 812 | Alive |
| 14 | 61 | M | 32 |
Lower DVT (Unilateral femoral vein) |
6 | Hypertension |
Non mechanical (CPAP) |
25 | 15 |
Fondaparinux (2.5 mg/day) |
Infectious Diseases | 81 | 249 | 415.0 | 9.8 | 258 | Alive |
| 15 | 44 | M | 34 |
Upper DVT (Unilateral axillar vein) |
5 | None | Mechanical | 29 | 19 |
Enoxaparin (4000 UI/day) |
Internal Medicine | 59 | 503 | 231.8 | 42.0 | 936 | Alive |
| 16 | 79 | F | 31 |
Lower DVT (Unilateral femoral–popliteal axis) |
8 | Hypertension |
Non mechanical (CPAP) |
16 | 0 | None | Internal Medicine | 227 | 172 | 860.0 | 20.2 | 555 | Dead |
| 17 | 78 | M | 24 |
Upper DVT (Unilateral subclavian–axillar axis) |
6 |
Hypertension, dyslipidaemia |
Non mechanical (CPAP) |
15 | 8 |
Enoxaparin (4000 UI/day) |
Internal Medicine | 65 | 138 | 76.7 | 27.5 | 472 | Alive |
| 18 | 84 | F | 24 |
Lower DVT (Bilateral femoral vein) |
6 | None |
Non mechanical (CPAP) |
15 | 8 |
Enoxaparin (4000 UI/day) |
Internal Medicine | 332 | 100 | 131.6 | 18.1 | 1124 | Alive |
| 19 | 45 | M | 24 |
PE (Bilateral subsegmental PE) |
5 | HBV-related chronic liver disease |
Non mechanical (CPAP) |
30 | 20 |
Enoxaparin (4000 UI/day) |
Infectious Diseases | 300 | 598 | 738.3 | 44.5 | 494 | Alive |
| 20 | 66 | M | 29 |
Upper DVT (Unilateral subclavian–jugular axis) |
6 | Dyslipidaemia | Mechanical | 13 | 3 |
Calcic heparin (5000 UI × 3/day) |
ICU | 48 | 146 | 486.7 | 24.6 | 1162 | Alive |
| 21 | 69 | M | 31 |
Upper DVT (Unilateral subclavian vein) |
6 | Hypertension | Mechanical | 14 | 4 |
Calcic heparin (7500 UI × 3/day) |
Internal Medicine | 93 | 244 | 196.8 | 47.6 | 645 | Alive |
| 22 | 48 | M | 27 |
Upper and lower DVT (Unilateral axillar vein and unilateral femoral–popliteal axis) |
6 | None | Mechanical | 28 | 18 |
Calcic heparin (5000 UI × 3/day) |
Infectious Diseases | 74 | 218 | 311.4 | 34.9 | 590 | Alive |
| 23 | 51 | F | 24 |
Upper and lower DVT (Unilateral axilla–subclavian axis and unilateral femoral vein) |
5 | None | Mechanical | 16 | 6 |
Calcic heparin (5000 UI × 3/day) |
Pneumology | 112 | 218 | 145.3 | 13.1 | 4641 | Alive |
| 24 | 59 | M | 30 |
Upper DVT (Unilateral subclavian–axillar axis) |
6 | Hypertension | Mechanical | 15 | 5 |
Enoxaparin (4000 UI/day) |
Internal Medicine | 105 | 304 | 950.0 | 40.6 | 783 | Alive |
| 25 | 64 | M | 25 | PE (Lobar PE) and portal vein thrombosis | 5 | Rendu Osler disease, hypertension |
Non mechanical (Venturi mask) |
11 | 1 |
Enoxaparin (4000 UI/day) |
Internal Medicine | 385 | 80 | 114.3 | 24.9 | 582 | Alive |
CPAP continuous positive airway pressure, CRP C-reactive protein, DM2 diabetes mellitus type 2, DVT deep vein thrombosis, ICU intensive care unit, LDH lactate dehydrogenase, OSAS obstructive sleep apnea syndrome, PaO2/FiO2 arterial oxygen partial pressure to fractional inspired oxygen ratio, PE pulmonary embolism, PLR platelet-to-lymphocyte ratio, PLT platelet, VTE venous thromboembolism